RhumbLine Advisers’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,281
| Closed | -$44.5K | – | 4273 |
|
|
2025
Q1 | $44.5K | Buy |
6,281
+323
| +5% | +$2.29K | ﹤0.01% | 3603 |
|
|
2024
Q4 | $131K | Buy |
5,958
+9
| +0.2% | +$198 | ﹤0.01% | 3391 |
|
|
2024
Q3 | $119K | Sell |
5,949
-293
| -5% | -$5.88K | ﹤0.01% | 3451 |
|
|
2024
Q2 | $109K | Buy |
6,242
+795
| +15% | +$13.8K | ﹤0.01% | 3499 |
|
|
2024
Q1 | $227K | Buy |
5,447
+101
| +2% | +$4.21K | ﹤0.01% | 3108 |
|
|
2023
Q4 | $135K | Hold |
5,346
| – | – | ﹤0.01% | 3352 |
|
|
2023
Q3 | $175K | Buy |
5,346
+215
| +4% | +$7.03K | ﹤0.01% | 3231 |
|
|
2023
Q2 | $299K | Buy |
+5,131
| New | +$299K | ﹤0.01% | 3021 |
|
|
2021
Q2 | – | Sell |
-688
| Closed | -$178K | – | 3118 |
|
|
2021
Q1 | $178K | Sell |
688
-25
| -4% | -$6.47K | ﹤0.01% | 2859 |
|
|
2020
Q4 | $138K | Buy |
713
+113
| +19% | +$21.9K | ﹤0.01% | 2918 |
|
|
2020
Q3 | $122K | Sell |
600
-52
| -8% | -$10.6K | ﹤0.01% | 2833 |
|
|
2020
Q2 | $182K | Buy |
+652
| New | +$182K | ﹤0.01% | 2806 |
|